menu
    • menu
    [{"orgOrder":0,"company":"GID BIO","sponsor":"Richard King Mellon Foundation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Autologous stromal vascular fraction cell therapy","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"GID BIO","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GID BIO \/ Richard King Mellon Foundation","highestDevelopmentStatusID":"1","companyTruncated":"GID BIO \/ Richard King Mellon Foundation"}]

    Find Clinical Drug Pipeline Developments & Deals by GID BIO

    Menu

    GID BIO

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GID BIO

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            GID BIO

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous stromal vascular fraction cell therapy

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Undisclosed

                            Sponsor : Richard King Mellon Foundation

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Gid Bio Wins Funding from Richard King Mellon Foundation to Study Regenerative Medicine to Treat Severe Respir...

                            Details : The funding will support pivotal/Phase III cellular therapy study that uses an intravenous injection of autologous stromal vascular fraction (SVF) cells, derived at point-of-care using the GID BIO SVF-2 technology platform.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 18, 2020

                            Lead Product(s) : Autologous stromal vascular fraction cell therapy

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Richard King Mellon Foundation

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth